SkinBioTherapeutics

Expanded enrolment for AxisBiotix-PsT study

RNS Number : 4563N
SkinBioTherapeutics PLC
01 February 2021
 


1 February 2021

 

SkinBioTherapeutics plc

 

("SkinBioTherapeutics" or "the Company")

 

Expanded enrolment for AxisBiotix-Ps™ food supplement consumer study

 

· Study size increased to 250 from 200, following high demand for places

· Study to commence by end February 2021

· Participants' feedback on AxisBiotix-Ps™ to be monitored through smart devices

 

SkinBioTherapeutics plc (AIM: SBTX ) , a life science company focused on skin health, announces that AxisBiotix Limited, a wholly owned subsidiary of the Company, has increased the size of its food supplement consumer study from 200 to 250 participants, following a high level of demand .

Further to research exploring the relationship between the gut and the skin, SkinBioTherapeutics with its partner Winclove Probiotics B.V., developed a blend of bacterial strains in the form of a food supplement. The proprietary blend of bacterial strains has been specifically designed to balance the gut microbiome to address the over-production of new skin cells often seen in aggressive skin conditions such as psoriasis.

 

Enrolment for the 'self-managed' food supplement consumer study commenced 13 January 2021, via a dedicated website www.axisbiotix.com . There has been a high level of demand for places and consequently, the Company has extended the study size from its initial target.

 

The study will be monitored through a mobile device app, involving periodic questions for participants evaluating the progression of their symptoms, and the submission of photographs of affected areas.

 

Winclove is expecting to ship the product to the Company by mid-February. The supplements will then be dispatched to the study participants, with an expected study start date by the end of February 2021. The study will conclude before the end of April 2021 and the Company expects to be able to report on the study findings shortly thereafter.

 

Subject to a positive outcome, the Company will then target a commercial launch of the product during the course of 2021.

 

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"I am overwhelmed by the response to the study. We received an extraordinary number of applicants in a very short period of time, the majority of which were psoriasis sufferers.

"The high demand for places on the study underlines just how prevalent skin conditions such as psoriasis are, and how keen sufferers are to try something new and natural to alleviate their symptoms. If we can, we want to help as many people as possible.

"We now move to the formal commencement of the study in the coming weeks and look forward to working with the applicants with the aim of seeing positive progression of their symptoms."

 

-Ends-

 

For more information please contact:

SkinBioTherapeutics plc

Stuart J . Ashman, CEO

Doug Quinn, CFO

Tel: +44 (0) 161 468 2760

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Michael Johnson (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners

Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis 

Tel: +44 (0) 20 7457 2020

[email protected]

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Prof. Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit: www.skinbiotix.com .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDMFWFEFSEEF